CNS & Neurological Disorders - Drug Targets

(Formerly Current Drug Targets - CNS & Neurological Disorders)



Become EABM
Become Reviewer

Meet Our Editorial Board Member free to download

Volume:18   Issue: 10
Pp: 733-734
Gislaine Z. Réus
DOI: 10.2174/187152731810200102104356

Omega-3 Fatty Acids as Druggable Therapeutics for Neurodegenerative Disorders

Volume:18   Issue: 10
Pp: 735-749
Neha M. Chitre, Nader H. Moniri and Kevin S. Murnane*
DOI: 10.2174/1871527318666191114093749

Pharmacotherapy of Down’s Syndrome: When and Which?

Volume:18   Issue: 10
Pp: 750-757
Seyed K. Tayebati*, Alessandro Cecchi, Ilenia Martinelli, Elisa Carboni and Francesco Amenta
DOI: 10.2174/1871527318666191114092924

Neurobehavioral Consequences Associated with Long Term Tramadol Utilization and Pathological Mechanisms

Volume:18   Issue: 10
Pp: 758-768
Khadga Raj, Pooja Chawla and Shamsher Singh*
DOI: 10.2174/1871527318666191112124435

A Review for Lithium: Pharmacokinetics, Drug Design, and Toxicity

Volume:18   Issue: 10
Pp: 769-778
Jinhua Wen*, Darrell Sawmiller*, Brendan Wheeldon and Jun Tan
DOI: 10.2174/1871527318666191114095249

Structurally Related Edaravone Analogues: Synthesis, Antiradical, Antioxidant, and Copper-Chelating Properties

Volume:18   Issue: 10
Pp: 779-790
Alexandre LeBlanc, Miroslava Cuperlovic-Culf, Pier Jr. Morin and Mohamed Touaibia*
DOI: 10.2174/1871527318666191114092007

Acknowledgements to Reviewers free to download

Volume:18   Issue: 10
Pp: 808-812

DOI: 10.2174/187152731810200102110540